Skip to Main Content
Contribute Try STAT+ Today

Nearly two years after the Covid-19 pandemic prompted remote inspections of pharmaceutical production plants, an international coalition of regulators is recommending the approach be used to complement on-site visits for the foreseeable future.

Although remote inspections posed various limitations on medicines regulators in recent months, the strategy also yielded some productive insights, such as the use of digital technology to gather electronic clinical trial data and additional intelligence about manufacturing sites, according to a new “reflection paper” from the International Coalition of Medicine Regulatory Authorities.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment